Darunavir clinical trials
Also written Prezista, DRV and TMC114.
Counted the way a researcher would: Darunavir with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses Darunavir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Darunavir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 23 Jun 2006 · PREZISTA · NDA 021976 (FDA, Drugs@FDA)
- European Union
- 11 Feb 2007 · Prezista · EMEA/H/C/000707 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
97 studies that test it; most in 2008 (12)
| Year | Studies |
|---|---|
| 2001 | 1 |
| 2003 | 3 |
| 2005 | 4 |
| 2006 | 4 |
| 2007 | 4 |
| 2008 | 12 |
| 2009 | 11 |
| 2010 | 5 |
| 2011 | 9 |
| 2012 | 6 |
| 2013 | 2 |
| 2014 | 6 |
| 2015 | 7 |
| 2016 | 3 |
| 2017 | 4 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 4 |
| 2022 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 55 · Other 42
Tibotec Pharmaceuticals, Ireland (18) · Janssen Sciences Ireland UC (5) · Gilead Sciences (4) · ANRS, Emerging Infectious Diseases (4) · Janssen Research & Development, LLC (4) · Tibotec, Inc (4) · Kirby Institute (3) · ViiV Healthcare (3)
Often tested with
Tested in the same studies.
Ritonavir (43) · Cobicistat (19) · Emtricitabine (17) · Tenofovir alafenamide (13) · Etravirine (10) · Atazanavir (9) · Dolutegravir (8) · Raltegravir (7)
Related medicines
As reviewed, each with the page that says it.
- One of Protease Inhibitors source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 1
Studies that test Darunavir.
Studies
Open first, then newest update. How each study uses Darunavir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 97
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV TreatmentsRecruitingPhase 4Gilead SciencesNCT06337032Written as DRVHow we know
- An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in AfricaNot yet recruitingPhase 3University College, LondonNCT07792096Written as Darunavir (DRV)How we know
- Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-upRecruitingPhase 4Instituto Mexicano del Seguro SocialNCT07678268Written as Dual therapy: darunavir/cobicistat + lamivudineHow we know
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIVActive, not recruitingPhase 2/3Gilead SciencesNCT02016924Written as DRVHow we know
- Study Comparing Efficacy and Safety of Darunavir Boosted With Ritonavir to HART With 2 NRTI and Darunavir Boosted With Ritonavir in HIV-1 Infected Patients ANRS136CompletedPhase 3French National Agency for Research on AIDS and Viral HepatitisNCT00421551Written as DarunavirHow we know
- Prevention of Perinatal Transmission of HIV-1 Without Nucleoside Reverse Transcriptase InhibitorsCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02738502Written as darunavir monotherapyHow we know
- Evaluation of a Dose Reduction of Darunavir (400 mg/d) in Virologically Suppressed HIV-1 PatientsCompletedPhase 2ANRS, Emerging Infectious DiseasesNCT02384967Written as DarunavirHow we know
- A Bioequivalence Study of Darunavir, Emtricitabine, and Tenofovir Alafenamide, in the Presence of Cobicistat in Healthy ParticipantsCompletedPhase 1Janssen Sciences Ireland UCNCT02578550Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)How we know
- Study to Evaluate the Relative Bioavailability of Fixed-dose Combination Tablet Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) as a Whole Tablet, as a Split Tablet, and as Crushed Tablet in Healthy Adult ParticipantsCompletedPhase 1Janssen Scientific Affairs, LLCNCT02984852Written as Darunavir (DRV)How we know
- A Study of Darunavir in Combination With Cobicistat or Ritonavir, and Dabigatran Etexilate in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT04208061Written as DarunavirHow we know
- A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate AgentsCompletedPhase 1Janssen Research & Development, LLCNCT04661397Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDCHow we know
- A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed ConditionsCompletedPhase 1Janssen Research & Development, LLCNCT04718805Written as DarunavirHow we know
- Body Composition Sub-study of the D2EFT TrialCompletedPhase 4Kirby InstituteNCT03675815Written as Darunavir (DRV) 800 milligram (MG) Oral TabletHow we know
- Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)CompletedPhase 4The Crofoot Research Center, Inc.NCT04388904Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (FDC)How we know
- HERV-K Suppression Using Antiretroviral Therapy in Volunteers With Amyotrophic Lateral Sclerosis (ALS)CompletedPhase 1National Institute of Neurological Disorders and Stroke (NINDS)NCT02437110Written as DarunavirHow we know
- Second-line Treatment of HIV-1 With Ritonavir Boosted Atazanavir or Darunavir With an Optimized NRTI BackboneWithdrawnPhase 3Bristol-Myers SquibbNCT01605084Written as DarunavirHow we know
- Dolutegravir and Darunavir Evaluation in Adults Failing TherapyStatus unknownPhase 4Kirby InstituteNCT03017872Written as DarunavirHow we know
- TMC114IFD3001 - Study Providing Continued Access to Treatment With Darunavir (DRV)/Ritonavir(Rtv) in HIV1 Infected Adults, Adolescents and Children Aged 3 Years or Above and Coming From Previous Company Sponsored Studies With DRVCompletedPhase 3Janssen Sciences Ireland UCNCT01281813Written as DarunavirHow we know
- A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy ParticipantsCompletedPhase 1Janssen Research & Development, LLCNCT05378906Written as DRVHow we know
- A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected SubjectsCompletedPhase 3Janssen Sciences Ireland UCNCT02431247Written as Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDCHow we know
See all 97 studies that test Darunavir →
Given beside what is tested · 13 — Darunavir is usual care or a partner of the new treatment
- Bone, Immunologic, and Virologic Effects of a Antiretroviral RegimenCompletedPhase 2Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsNCT01400412Written as DarunavirHow we know
- Safety and Efficacy of Doravirine (MK-1439) in Participants With Human Immunodeficiency Virus 1 (HIV-1) (MK-1439-018)CompletedPhase 3Merck Sharp & Dohme LLCNCT02275780Written as DarunavirHow we know
- Bioequivalence Study of GP30101 800 mg (GEROPHARM) Versus PREZISTA® 800 mg ("Jonson&Jonson", Russia)CompletedNot applicableGeropharmNCT04268472Written as Prezista®How we know
- Dual Therapy With Boosted Darunavir + DolutegravirCompletedPhase 3Technical University of MunichNCT02486133Written as PrezistaHow we know
- Efficacy of VHM After Treatment Interruption in Subjects Initiating ART During Acute HIV InfectionCompletedPhase 1/2SEARCH Research FoundationNCT02475915Written as DarunavirHow we know
- Study to Evaluate the Efficacy of GS-9131 Functional Monotherapy in Human Immunodeficiency Virus (HIV)-1-Infected Adults Failing a Nucleos(t)Ide Reverse Transcriptase Inhibitor-Containing Regimen With Nucleos(t)Ide Reverse Transcriptase Inhibitor Resistant VirusTerminatedPhase 2Gilead SciencesNCT03472326Written as DRVHow we know
- Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected AdultsCompletedPhase 3Gilead SciencesNCT01440569Written as DRVHow we know
- Cobicistat-containing Highly Active Antiretroviral Regimens in HIV-1 Infected Patients With Mild to Moderate Renal ImpairmentCompletedPhase 3Gilead SciencesNCT01363011Written as DRVHow we know
- Standard Antiretroviral v. Multi-class Therapy in Acutely HIV-1 Infected Antiretroviral-Naïve Subjects (ADARC 2007-01)CompletedNot applicableRockefeller UniversityNCT00525733Written as darunavir 800 mgHow we know
- Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.CompletedPhase 1/2Gilead SciencesNCT01565889Written as DRVHow we know
- Raltegravir And Darunavir Antiretroviral in Antiretroviral Naive PatientsCompletedPhase 4Dallas VA Medical CenterNCT00677300Written as DarunavirHow we know
- Enfuvirtide/Current Protease Inhibitor Switch to PREZISTA (Darunavir)/Ritonavir + TMC125 in HIV Patients With Enfuvirtide Side Effects.CompletedPhase 3Tibotec, IncNCT00460746Written as TMC125, Darunavir; RitonavirHow we know
- A Study to Assess the Bioequivalence of Darunavir When Co-Administrated With Cobicistat Under Fed and Fasted ConditionsCompletedPhase 1Janssen R&D IrelandNCT01619527Written as darunavirHow we know
As the comparator · 7 — what is tested is compared with Darunavir
- Ndovu RCT: Investing the Optimal Management of Dolutegravir ResistanceRecruitingPhase 3University of NairobiNCT06747507Written as Darunavir+RitonavirHow we know
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV NaiveWithdrawnPhase 4Juan A. ArnaizNCT02470650Written as DarunavirHow we know
- A Prospective, Open-label Trial of Two ABC/3TC Based Regimens in Late Presenter naïve Patients (CD4 <200 Cells/µL)CompletedPhase 3University of Modena and Reggio EmiliaNCT01900106Written as abacavir/lamivudine + darunavir/ritonavirHow we know
- Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)TerminatedPhase 2Merck Sharp & Dohme LLCNCT02116660Written as DarunavirHow we know
- Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive SubjectsCompletedPhase 3ViiV HealthcareNCT01449929Written as darunavir 800mg OADHow we know
- D/C/F/TAF Versus COBI-boosted DRV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment Naive AdultsCompletedPhase 2Gilead SciencesNCT01565850Written as DRVHow we know
- Effects of Steady State Tipranavir/Ritonavir or Darunavir/Ritonavir or Ritonavir on Platelet Function, Coagulation and Fibrinolysis Biomarkers in Healthy SubjectsCompletedPhase 1Boehringer IngelheimNCT02251795Written as DarunavirHow we know
Codes
What other systems call Darunavir · ClinicalTrials.gg INT006585
- MeSH (NLM) D000069454DarunavirConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) YO603Y8113DARUNAVIRConfirmed FDA, NLM, Wikidata
- RxNorm 460132Confirmed FDA, Wikidata
- Wikidata Q3765251darunavirConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C65364DarunavirOne source FDA
- DrugBank DB01264One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069454 | Darunavir | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | YO603Y8113 | DARUNAVIR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 460132 | — | Confirmed FDA, Wikidata |
| Wikidata | Q3765251 | darunavir | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C65364 | Darunavir | One source FDA |
| DrugBank | DB01264 | — | One source Wikidata |
Also registered as darunavir ethanolate (UNII 33O78XF0BW · RxNorm 644682).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.